Drug firm compensates patients for suspected hepatitis B vaccine failure.
Durand de Bousingen
D
D
D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence*; D005260:Female; D005602:France; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008318:Malpractice; D009103:Multiple Sclerosis / Q000209:etiology*; D010344:Patient Advocacy / Q000191:economics / Q000331:legislation & jurisprudence; D017211:Treatment Failure
D017325:Hepatitis B Vaccines